Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

NCT00348595 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

77

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Revlimid

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]